Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 836858 |
Synonyms | |
Therapy Description |
BI 836858 is a human antibody against CD33 that induces cytotoxic immune response against CD33-positive tumor cells (PMID: 27013443, PMID: 29515764). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 836858 | BI836858 | CD33 Antibody 13 | BI 836858 is a human antibody against CD33 that induces cytotoxic immune response against CD33-positive tumor cells (PMID: 27013443, PMID: 29515764). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01690624 | Phase I | BI 836858 | BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse | Completed | USA | 0 |
NCT02240706 | Phase II | BI 836858 | Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes | Terminated | USA | DEU | 0 |